FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time.

A replay of the call will be available on the Events section of the company’s investor relations website.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes its lead asset, iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Additional radiotherapeutics are in development utilizing alpha emitters and Auger emitters to target solid tumors.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

MEDIA:
Christy Maginn
Bliss Bio Health
703-297-7194
This email address is being protected from spambots. You need JavaScript enabled to view it.

INVESTORS:
Anne Marie Fields
Precision AQ (formerly Stern IR)
This email address is being protected from spambots. You need JavaScript enabled to view it.